PE20130497A1 - Combinaciones que comprenden antipsicoticos y agonistas de taar1 - Google Patents
Combinaciones que comprenden antipsicoticos y agonistas de taar1Info
- Publication number
- PE20130497A1 PE20130497A1 PE2013000163A PE2013000163A PE20130497A1 PE 20130497 A1 PE20130497 A1 PE 20130497A1 PE 2013000163 A PE2013000163 A PE 2013000163A PE 2013000163 A PE2013000163 A PE 2013000163A PE 20130497 A1 PE20130497 A1 PE 20130497A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- oxazol
- dihydro
- lower alkyl
- combinations including
- Prior art date
Links
- 101000890887 Homo sapiens Trace amine-associated receptor 1 Proteins 0.000 title abstract 2
- 102100040114 Trace amine-associated receptor 1 Human genes 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 239000000164 antipsychotic agent Substances 0.000 title 1
- 229940005529 antipsychotics Drugs 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- -1 (S) -2-PHENYL-BUTYL Chemical class 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960005017 olanzapine Drugs 0.000 abstract 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN FARMACO ANTIPSICOTICO ATIPICO TAL COMO OLANZAPINA; Y B) UN AGONISTA DEL RECEPTOR 1 ASOCIADO A AMINAS TRAZA (TAAR1) DE FORMULA (I) DONDE R1 ES H, DEUTERIO, ALQUILO INFERIOR, HALOGENO, HIDROXI, ENTRE OTROS; R2 ES H, FENILO O ALQUILO INFERIOR; X ES UN ENLACE, -OCH2-, -CH2CH2CH2-, -S(O)2CH2-, ENTRE OTROS; Y ES FENILO, NAFTILO, TIOFENILO, PIRIDINILO, ENTRE OTROS; n ES DE 0 A 3; SIENDO COMPUESTOS PREFERIDOS: (S)-4-((S)-2-FENIL-BUTIL)-4,5-DIHIDRO-OXAZOL-2-ILAMINA, (S)-1-(4-FLUOROBENCIL)-3-(4-(MORFOLIN-2-IL)FENIL)UREA, {4-[2-((S)-2-AMINO-4,5-DIHIDRO-OXAZOL-4-IL)-ETIL]-FENIL}-AMIDA DE ACIDO 5-CLORO-PIRIMIDIN-2-CARBOXILICO, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ESQUIZOFRENIA, EPISODIOS DE MANIA ASOCIADOS AL TRASTORNO BIPOLAR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10171560 | 2010-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130497A1 true PE20130497A1 (es) | 2013-04-22 |
Family
ID=44512842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000163A PE20130497A1 (es) | 2010-08-02 | 2011-07-26 | Combinaciones que comprenden antipsicoticos y agonistas de taar1 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9132136B2 (es) |
| EP (1) | EP2600853A1 (es) |
| JP (2) | JP5749802B2 (es) |
| KR (1) | KR101455548B1 (es) |
| CN (1) | CN103068379A (es) |
| AR (1) | AR082458A1 (es) |
| AU (1) | AU2011287701A1 (es) |
| BR (1) | BR112013002518A2 (es) |
| CA (1) | CA2802935A1 (es) |
| CL (1) | CL2013000313A1 (es) |
| CO (1) | CO6761298A2 (es) |
| CR (1) | CR20120663A (es) |
| EA (1) | EA024703B1 (es) |
| EC (1) | ECSP13012414A (es) |
| MA (1) | MA34458B1 (es) |
| MX (1) | MX340489B (es) |
| MY (1) | MY166955A (es) |
| NZ (1) | NZ604592A (es) |
| PE (1) | PE20130497A1 (es) |
| PH (1) | PH12013500043A1 (es) |
| SG (1) | SG187125A1 (es) |
| TW (1) | TWI511728B (es) |
| UA (1) | UA112527C2 (es) |
| WO (1) | WO2012016879A1 (es) |
| ZA (1) | ZA201300431B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2890438B2 (ja) | 1989-02-16 | 1999-05-17 | 東陶機器株式会社 | 流量制御ノズル |
| JP3072762B2 (ja) | 1989-02-16 | 2000-08-07 | 東陶機器株式会社 | 流量制御ノズル |
| US8802673B2 (en) * | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| BR112014015832A8 (pt) | 2012-01-12 | 2017-07-04 | Hoffmann La Roche | derivados heterocíclicos como receptores associados com aminas vistigiais (taars) |
| MY170491A (en) * | 2012-11-16 | 2019-08-08 | Hoffmann La Roche | Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters |
| PL3080284T3 (pl) | 2013-12-11 | 2018-05-30 | F.Hoffmann-La Roche Ag | Sposób wytwarzania chiralnej 2-(4-aminofenylo)morfoliny |
| WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| US10858326B2 (en) * | 2016-05-04 | 2020-12-08 | Purdue Pharma L.P. | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof |
| CA3091292A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
| EA202092490A1 (ru) | 2018-04-18 | 2020-12-23 | Констеллейшен Фармасьютикалс, Инк. | Модуляторы метилмодифицирующих ферментов, композиции и их применения |
| CN120097995A (zh) | 2018-05-21 | 2025-06-06 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| WO2021159015A1 (en) * | 2020-02-07 | 2021-08-12 | Cytokinetics, Inc. | Nampt modulators |
| MX2022012833A (es) | 2020-04-14 | 2022-11-07 | Sunovion Pharmaceuticals Inc | (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos. |
| CA3178004A1 (en) * | 2020-05-09 | 2021-11-18 | Taolei Sun | Treatment of adverse effects caused by atypical antipsychotics |
| EP4317164A4 (en) * | 2021-03-29 | 2024-07-31 | Shujing Biopharma Co., Ltd | Spiro-containing derivative, and preparation method therefor and use thereof |
| CN114288304A (zh) * | 2021-12-31 | 2022-04-08 | 江苏海洋大学 | 一种抗精神分裂症组合物及其应用 |
| AR129909A1 (es) | 2022-07-15 | 2024-10-09 | Hoffmann La Roche | Cetorreductasa mutante con mayor actividad de cetorreductasa así como métodos y usos de esta |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1838716E (pt) | 2005-01-05 | 2011-07-15 | Lilly Co Eli | Di-hidrato de pamoato de olanzapina |
| BRPI0610780A2 (pt) * | 2005-04-22 | 2016-09-06 | Teva Pharma | formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete |
| KR20070022539A (ko) | 2005-08-22 | 2007-02-27 | 홍진표 | 지프라시돈 또는 그의 대사산물을 함유하는 항비만 조성물 |
| CN101600700B (zh) | 2007-02-02 | 2013-08-21 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体用于cns病症的新的2-氨基噁唑啉 |
| WO2008098857A1 (en) | 2007-02-15 | 2008-08-21 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| EP2182935A1 (en) | 2007-08-02 | 2010-05-12 | F. Hoffmann-Roche AG | The use of benzamide derivatives for the treatment of cns disorders |
| BRPI0916363A2 (pt) | 2008-07-24 | 2018-05-29 | Hoffmann La Roche | derivados de 4,5-di-hidro-oxazol-2-ila |
| CA2733378C (en) | 2008-08-05 | 2017-04-25 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US8293954B2 (en) * | 2010-03-10 | 2012-10-23 | Honeywell International Inc. | Catalyst life improvement for the vapor phase manufacture of 1-chloro-3,3,3-trifluoropropene |
-
2011
- 2011-07-25 US US13/189,600 patent/US9132136B2/en not_active Expired - Fee Related
- 2011-07-26 MY MYPI2013000176A patent/MY166955A/en unknown
- 2011-07-26 KR KR1020137005202A patent/KR101455548B1/ko not_active Expired - Fee Related
- 2011-07-26 BR BR112013002518A patent/BR112013002518A2/pt not_active IP Right Cessation
- 2011-07-26 CA CA2802935A patent/CA2802935A1/en not_active Abandoned
- 2011-07-26 WO PCT/EP2011/062772 patent/WO2012016879A1/en not_active Ceased
- 2011-07-26 MX MX2013000745A patent/MX340489B/es active IP Right Grant
- 2011-07-26 EA EA201291476A patent/EA024703B1/ru not_active IP Right Cessation
- 2011-07-26 JP JP2013522196A patent/JP5749802B2/ja not_active Expired - Fee Related
- 2011-07-26 CN CN2011800369576A patent/CN103068379A/zh active Pending
- 2011-07-26 MA MA35646A patent/MA34458B1/fr unknown
- 2011-07-26 EP EP11741429.2A patent/EP2600853A1/en not_active Withdrawn
- 2011-07-26 AU AU2011287701A patent/AU2011287701A1/en not_active Abandoned
- 2011-07-26 NZ NZ604592A patent/NZ604592A/en not_active IP Right Cessation
- 2011-07-26 SG SG2013003983A patent/SG187125A1/en unknown
- 2011-07-26 PE PE2013000163A patent/PE20130497A1/es not_active Application Discontinuation
- 2011-07-26 PH PH1/2013/500043A patent/PH12013500043A1/en unknown
- 2011-07-26 UA UAA201302435A patent/UA112527C2/uk unknown
- 2011-07-29 TW TW100127153A patent/TWI511728B/zh not_active IP Right Cessation
- 2011-08-02 AR ARP110102780 patent/AR082458A1/es unknown
-
2012
- 2012-12-18 CO CO12229429A patent/CO6761298A2/es unknown
- 2012-12-21 CR CR20120663A patent/CR20120663A/es unknown
-
2013
- 2013-01-16 ZA ZA2013/00431A patent/ZA201300431B/en unknown
- 2013-01-31 CL CL2013000313A patent/CL2013000313A1/es unknown
- 2013-02-01 EC ECSP13012414 patent/ECSP13012414A/es unknown
- 2013-07-19 US US13/946,471 patent/US20130345201A1/en not_active Abandoned
-
2015
- 2015-04-08 JP JP2015079114A patent/JP2015145408A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA34458B1 (fr) | 2013-08-01 |
| BR112013002518A2 (pt) | 2016-05-31 |
| MY166955A (en) | 2018-07-25 |
| JP2013536181A (ja) | 2013-09-19 |
| EA024703B1 (ru) | 2016-10-31 |
| SG187125A1 (en) | 2013-02-28 |
| TW201206912A (en) | 2012-02-16 |
| CL2013000313A1 (es) | 2013-05-03 |
| US20130345201A1 (en) | 2013-12-26 |
| PH12013500043A1 (en) | 2019-06-03 |
| AR082458A1 (es) | 2012-12-12 |
| NZ604592A (en) | 2015-02-27 |
| WO2012016879A1 (en) | 2012-02-09 |
| CN103068379A (zh) | 2013-04-24 |
| US20120028964A1 (en) | 2012-02-02 |
| JP2015145408A (ja) | 2015-08-13 |
| UA112527C2 (uk) | 2016-09-26 |
| CR20120663A (es) | 2013-04-01 |
| KR101455548B1 (ko) | 2014-10-27 |
| CA2802935A1 (en) | 2012-02-09 |
| MX340489B (es) | 2016-07-11 |
| CO6761298A2 (es) | 2013-09-30 |
| ECSP13012414A (es) | 2013-03-28 |
| MX2013000745A (es) | 2013-03-05 |
| EA201291476A1 (ru) | 2013-06-28 |
| TWI511728B (zh) | 2015-12-11 |
| JP5749802B2 (ja) | 2015-07-15 |
| KR20130070629A (ko) | 2013-06-27 |
| ZA201300431B (en) | 2013-09-25 |
| AU2011287701A1 (en) | 2013-01-10 |
| EP2600853A1 (en) | 2013-06-12 |
| US9132136B2 (en) | 2015-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130497A1 (es) | Combinaciones que comprenden antipsicoticos y agonistas de taar1 | |
| PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
| PE20081752A1 (es) | Sal de napadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2-(1h)-ona como agonista del receptor adrenergico b2 | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20130215A1 (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta2 y como antagonistas muscarinicos m3 | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20090449A1 (es) | Agonistas de receptor acoplado a proteina g gpr119 de piridona | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20110341A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
| NZ588652A (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
| PE20091656A1 (es) | Compuestos heterociclicos como inhibidores de la cinasa raf | |
| PE20110419A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk | |
| PE20141361A1 (es) | Compuesto heterociclico dihidroxi aromatico | |
| PE20090717A1 (es) | Derivados de quinolina como inhibidores de la pi3 quinasa | |
| PE20140865A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| PE20130279A1 (es) | Compuestos heteroarilo nitrogenados | |
| PE20120008A1 (es) | Derivados de fenoxi bencenosulfonamida | |
| PE20110404A1 (es) | Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de la orexina | |
| PE20081659A1 (es) | Agonistas de gpcr | |
| PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
| PE20110328A1 (es) | Compuestos heterociclicos fusionados como moduladores del receptor de la orexina | |
| PE20080056A1 (es) | Derivados de cromencarboxamida como antagonistas del receptor s1p1 | |
| PE20080186A1 (es) | Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |